Long-term survival of uveal melanoma patients after surgery for liver metastases.
S Frenkel, I Nir, K Hendler...
https://pubmed.ncbi.nlm.nih.gov/19429579Actively Recruiting
All Genders
ID01438658
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Led by Hadassah Medical Organization · Updated on 2011-09-28
250
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Uveal melanoma is the most common primary eye tumor in adults. Although local treatments can be effective, patients often die from metastatic disease. Researchers are studying whether certain serum biomarkers can help detect metastases earlier than current imaging methods, potentially leading to earlier treatment and improved survival. This observational study aims to assess if changes in biomarker levels can predict metastases before they are visible on scans. Participants will be monitored as a single group without any experimental treatments. The study observes changes in specific blood markers over time to determine if these can signal the development of metastatic uveal melanoma. This approach may identify metastases up to 12 months before imaging can detect them, allowing for earlier intervention. During the study, participants will have their blood drawn regularly to measure biomarker levels. Researchers will compare these levels to imaging results to see if biomarker changes correspond with metastases diagnosis. The main outcome is whether a significant increase in biomarker levels can be linked to metastases detected by imaging up to a year earlier. The study is observational and does not involve any treatment; participants will continue their standard care throughout. The study may continue until December 2040.
CONDITIONS
Brief Title
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Diagnosis of uveal melanoma
You will not qualify if you...
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Up to 12 months
Participants are observed over time to assess serum biomarker levels and their association with the detection of metastatic uveal melanoma.
Trial Site Locations
Total: 1 location
1
Specialized Ocular Oncology Service, Hadassah-Hebrew-University Medical Center
Jerusalem, Israel, 91120
Actively Recruiting
Loading map...
Research Team
S
Shahar Frenkel, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie.
P Mariani, S Piperno-Neumann, V Servois...
https://pubmed.ncbi.nlm.nih.gov/19329272Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Ingrid Haritoglou, Armin Wolf, Tanja Maier...
https://pubmed.ncbi.nlm.nih.gov/19270465